Trial results

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047 on ClinicalTrials.gov · last registry update 2026-08-13

An unusually large phase 2: 299 participants, more than double the 114 typical for the stage. The sponsor logged completion for 19 September 2025. Primary outcome, as filed: Change in Glycated haemoglobin (HbA1c). tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

299

Started

2024-03-18

Primary completion

2025-09-19 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycated haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.